The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 29, 2015

Filed:

Oct. 04, 2013
Applicant:

Ugp Therapeutics, Inc., Chicago, IL (US);

Inventors:

Nozer M. Mehta, Randolph, NJ (US);

James P. Gilligan, Union, NJ (US);

Assignee:

UGP Therapeutics, Inc., Chicago, IL (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/23 (2006.01); A61K 31/65 (2006.01); C07K 14/585 (2006.01); A61P 19/02 (2006.01); A61K 45/06 (2006.01); A61K 31/381 (2006.01); A61K 31/404 (2006.01); A61K 31/415 (2006.01); A61K 31/573 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
A61K 38/23 (2013.01); A61K 31/381 (2013.01); A61K 31/404 (2013.01); A61K 31/415 (2013.01); A61K 31/573 (2013.01); A61K 31/65 (2013.01); A61K 38/17 (2013.01); A61K 45/06 (2013.01);
Abstract

Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a cyclooxygenase-2 (COX-2) inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent. The methods disclosed herein for treating inflammatory or degenerative diseases in a subject include administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and co-administering, as part of a combination therapy, a therapeutically effective amount of a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid to the subject.


Find Patent Forward Citations

Loading…